AP2218A - Azithromycin dosage forms with reduced side effects - Google Patents
Azithromycin dosage forms with reduced side effectsInfo
- Publication number
- AP2218A AP2218A APAP/P/2004/003145A AP2004003145A AP2218A AP 2218 A AP2218 A AP 2218A AP 2004003145 A AP2004003145 A AP 2004003145A AP 2218 A AP2218 A AP 2218A
- Authority
- AP
- ARIPO
- Prior art keywords
- azithromycin
- alkalizing agent
- effective amount
- dosage form
- glyceryl
- Prior art date
Links
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title abstract 13
- 229960004099 azithromycin Drugs 0.000 title abstract 13
- 230000000694 effects Effects 0.000 title abstract 3
- 239000002552 dosage form Substances 0.000 title 1
- 230000003113 alkalizing effect Effects 0.000 abstract 6
- 239000003795 chemical substances by application Substances 0.000 abstract 6
- 239000006186 oral dosage form Substances 0.000 abstract 5
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 4
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 abstract 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 2
- 230000002496 gastric effect Effects 0.000 abstract 2
- 229940081618 glyceryl monobehenate Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960000502 poloxamer Drugs 0.000 abstract 2
- 229920001983 poloxamer Polymers 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229940100692 oral suspension Drugs 0.000 abstract 1
- 229940059096 powder for oral suspension Drugs 0.000 abstract 1
- 208000028172 protozoa infectious disease Diseases 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule. Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent. Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent. Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52708403P | 2003-12-04 | 2003-12-04 | |
| PCT/IB2004/001654 WO2005053650A1 (en) | 2003-12-04 | 2004-05-14 | Azithromycin dosage forms with reduced side effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2004003145A0 AP2004003145A0 (en) | 2004-09-30 |
| AP2218A true AP2218A (en) | 2011-04-20 |
Family
ID=34699855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2004/003145A AP2218A (en) | 2003-12-04 | 2004-05-14 | Azithromycin dosage forms with reduced side effects |
Country Status (8)
| Country | Link |
|---|---|
| CN (1) | CN1697648B (en) |
| AP (1) | AP2218A (en) |
| AU (1) | AU2004216676B2 (en) |
| EC (1) | ECSP045351A (en) |
| GT (1) | GT200400183A (en) |
| TN (1) | TNSN05319A1 (en) |
| UA (1) | UA78793C2 (en) |
| ZA (1) | ZA200408075B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101340882B (en) * | 2005-12-22 | 2015-02-11 | 大塚制药株式会社 | Method for producing drug-containing wax-based particles, extruder used for the method, and sustained-release preparation containing cilostazol |
| CN103054813A (en) * | 2012-12-31 | 2013-04-24 | 广东先强药业有限公司 | Azithromycin oral sustained-release dry suspension and preparation method thereof |
| CN104177457A (en) * | 2013-05-23 | 2014-12-03 | 长春海悦药业有限公司 | Azithromycin drug raw material, and preparation and application thereof |
| EP3267997A4 (en) * | 2015-03-10 | 2018-08-15 | Lumos Pharma, Inc. | Cyclocreatine microsuspension |
| EP3576755A4 (en) * | 2017-02-02 | 2020-12-02 | McMaster University | BICARBONATE AS A POTENTIATOR FOR ANTIMICROBIAL INGREDIENTS |
| CN114213484A (en) * | 2021-12-21 | 2022-03-22 | 河北远征药业有限公司 | Tildipirosin 1, 2-propylene glycol solvent compound and preparation method thereof |
| CN115212173B (en) * | 2022-07-11 | 2024-10-15 | 上海现代药物制剂工程研究中心有限公司 | Ambroxol hydrochloride spherical slow-release particles, preparation method and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0679400A1 (en) * | 1994-04-29 | 1995-11-02 | Pfizer Inc. | Oral dosage forms of azithromycin avoiding drugfood interaction |
| US5633006A (en) * | 1992-07-30 | 1997-05-27 | Pfizer Inc. | Taste-masking composition of bitter pharmaceutical agents |
| WO2003063838A1 (en) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Dry granulated formulations of azithromycin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1123279A (en) * | 1995-06-15 | 1996-05-29 | 沈家祥 | Azithmycin water-soluble salt, injection thereof and their usage |
-
2004
- 2004-05-14 CN CN200480000209.2A patent/CN1697648B/en not_active Expired - Lifetime
- 2004-05-14 AP APAP/P/2004/003145A patent/AP2218A/en active
- 2004-05-14 AU AU2004216676A patent/AU2004216676B2/en not_active Expired
- 2004-05-14 UA UA20041210181A patent/UA78793C2/en unknown
- 2004-09-16 GT GT200400183A patent/GT200400183A/en unknown
- 2004-10-06 ZA ZA200408075A patent/ZA200408075B/en unknown
- 2004-10-08 EC ECSP045351 patent/ECSP045351A/en unknown
-
2005
- 2005-12-14 TN TNP2005000319A patent/TNSN05319A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5633006A (en) * | 1992-07-30 | 1997-05-27 | Pfizer Inc. | Taste-masking composition of bitter pharmaceutical agents |
| EP0679400A1 (en) * | 1994-04-29 | 1995-11-02 | Pfizer Inc. | Oral dosage forms of azithromycin avoiding drugfood interaction |
| WO2003063838A1 (en) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Dry granulated formulations of azithromycin |
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP045351A (en) | 2005-01-28 |
| AU2004216676B2 (en) | 2011-06-16 |
| UA78793C2 (en) | 2007-04-25 |
| CN1697648A (en) | 2005-11-16 |
| TNSN05319A1 (en) | 2007-07-10 |
| AP2004003145A0 (en) | 2004-09-30 |
| CN1697648B (en) | 2010-06-23 |
| GT200400183A (en) | 2005-10-24 |
| AU2004216676A1 (en) | 2005-06-23 |
| ZA200408075B (en) | 2007-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200518784A (en) | Azithromycin dosage forms with reduced side effects | |
| SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
| NZ524138A (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
| WO2011160136A3 (en) | Progesterone containing oral dosage forms and related methods | |
| BE2011C013I2 (en) | ||
| EP1708685A4 (en) | Effervescent oral opiate dosage forms and methods of administering opiates | |
| NZ620879A (en) | A novel formulation of indomethacin | |
| RU2011152105A (en) | COMPOSITIONS OF 3-CYANOCHINOLINE TABLETS AND THEIR APPLICATION | |
| NZ532063A (en) | Methods for wet granulating azithromycin | |
| WO2005055921A3 (en) | Compositions for treatment of ear disorders and methods of use thereof | |
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| AP2218A (en) | Azithromycin dosage forms with reduced side effects | |
| NZ595798A (en) | Ectoparasiticidal methods and formulations | |
| TW200503785A (en) | Dosage form containing (S)-pantoprazole as active ingredient | |
| PL1648473T3 (en) | Single dose fast dissolving azithromycin | |
| MX2007010886A (en) | Acarbose methods and formulations for treating chronic constipation. | |
| ES2179729B1 (en) | SOLID PHARMACEUTICAL FORM OF ORAL DISPERSABLE ADMINISTRATION IN WATER, WHICH INCLUDES RIFAMPICINE, ISONIAZIDE AND HYDROCHLORIDE PYRIDOXINE, PROCEDURE FOR OBTAINING AND FORM OF PRESENTATION OF SUCH PHARMACEUTICAL FORM. | |
| WO2003105811A8 (en) | Controlled release compositions and methods for using same | |
| RU2012136190A (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ARTHROZOARTHRITIS CONTAINING REBAMIPID AS AN ACTIVE INGREDIENT | |
| SE0103613D0 (en) | Novel formulation | |
| AP1820A (en) | Use of specific dose of fondaparinux sodium for the treatment of ACS. | |
| MD3121G2 (en) | Method of viral hepatitis B prophylaxis | |
| GB0224492D0 (en) | Pharmaceutical compositions of rapid drug delivery system to carry active ingredients for fast dissolving tablets by mouth administration | |
| TW200611686A (en) | Effervescent oral opiate dosage forms and methods of administering opiates | |
| WO2006036956A3 (en) | Therapeutic regimen for treating cancer using quassinoids and other chemotherapeutic agents |